ABCB1 and non-small cell lung carcinoma: In the chemotherapy regimen of non-small cell lung cancer, platinum drugs can be combined with vinorelbine, paclitaxel, and gemcitabine as the first-line treatment regimen[56] Our experimental results showed that MRTX849 was the substrate of ABCB1, and could competitively bind to the substrate binding site of ABCB1, thereby inhibiting the binding of other chemotherapeutic drugs with ABCB1, reducing drug efflux, promoting intracellular drug concentration and enhancing chemotherapy effect.